The disease burden and molecular rationale for GLP-2 targeting in SBS

Short bowel syndrome (SBS) is a severe malabsorptive disorder arising from extensive intestinal resection that leaves patients unable to maintain fluid, electrolyte, and macronutrient homeostasis on oral nutrition alone — creating a long-term dependency on parenteral nutrition (PN) and its associated clinical and economic burdens. Non-malignant SBS requiring home parenteral nutrition is estimated at 40 per million population in the U.S., with prevalence reported to have doubled over the past four decades, according to retrieved patent and academic literature.

The primary molecular target across the retrieved dataset is GLP-2 (glucagon-like peptide-2), an intestinotrophic hormone secreted by enteroendocrine L-cells. Academic literature identifies GLP-2’s mechanism as stimulation of intestinal crypt cell proliferation, inhibition of enterocyte apoptosis, reduction of gastrointestinal motility, and promotion of mucosal repair — collectively augmenting post-resection intestinal adaptation. GLP-2 receptor (GLP-2R) expression in the small intestinal and colonic mucosa is central to therapeutic response, with real-world receptor expression data in patient subgroups reported by University of Tübingen investigators using quantitative real-time PCR.

Patients with preserved colon (colon-in-continuity, or CiC anatomy) show distinct GLP-2R expression patterns relevant to drug dosing strategy, a finding that has driven dedicated patent families covering this patient subgroup. Secondary molecular targets emerging in the dataset include Wnt signaling, epidermal growth factor (EGF), and NOD2 — each representing a potential co-therapeutic or precision medicine lever for next-generation SBS programs, as documented by investigators at institutions including WIPO-registered patent holders and academic groups across Europe and Asia.

Glepaglutide, apraglutide, and the next-generation GLP-2 analog pipeline

The dominant therapeutic modality in SBS is subcutaneous administration of DPP-IV-degradation-resistant GLP-2 analogs, with teduglutide — a [Gly²]GLP-2 substituted analog — serving as the reference agent. A 2022 review from Tsinghua University specifically identifies glepaglutide and apraglutide as next-generation GLP-2 analogs under clinical-stage investigation in SBS, describing evidence-based medical findings supporting clinical guidelines for these agents in adult SBS. This paper represents the clearest retrieved signal of a beyond-teduglutide drug pipeline in this dataset.

“Glepaglutide and apraglutide represent the clearest clinical-stage beyond-teduglutide pipeline signals in this dataset — developers and IP strategists should monitor these programs as potential sources of new formulation, combination, and patient-stratification IP opportunities.”

The core molecular engineering strategy shared by teduglutide and next-generation analogs is resistance to dipeptidyl peptidase-IV (DPP-IV) degradation via N-terminal amino acid substitution — specifically the Ala²→Gly² substitution. Patent specifications from Shire-NPS describe h(Gly²)GLP-2 as the primary pharmacophore. The structural evolution from daily subcutaneous injection toward longer-acting formats signals a trajectory aimed at improving patient adherence and potentially enabling pre-surgical prophylactic use.

The pediatric dimension of this pipeline deserves specific attention. A systematic review from Meyer Children’s Hospital (Florence, 2022) confirms GLP-2 analog approval in pediatric patients in 2016 and evaluates PN-reduction efficacy across published pediatric literature — signalling that next-generation analogs with improved tolerability or dosing convenience could capture significant unmet clinical need in this subpopulation.

Peptibodies, dual agonists, and structural differentiation in the IP landscape

Two structurally distinct next-generation GLP-2 formats — Fc-fusion peptibodies and GLP-1/GLP-2 dual agonists — represent the most differentiated IP positions in the dataset, each with a different commercial rationale and competitive profile.

GLP-2 Fc-Fusion Peptibodies (Shire-NPS / Takeda)

Multiple active and pending patent families from Shire-NPS Pharmaceuticals and NPS Pharmaceuticals cover GLP-2 fusion proteins with immunoglobulin Fc domains. The key constructs are GLP-2 peptibody K274 (SEQ ID NO: 4) and GLP-2 peptibody B264 (SEQ ID NO: 2), both demonstrated in murine intestinal morphology experiments to markedly expand crypt and villus architecture versus untreated controls. The biological rationale for Fc fusion is extended plasma half-life, potentially enabling less frequent dosing than once-daily teduglutide.

Critically, these patent claims cover administration before, during, or after intestinal resection surgery — a perioperative indication that extends well beyond the chronic SBS maintenance indication of teduglutide. This signals an emerging strategy of early pharmacological intervention to limit the degree of intestinal failure at or before surgical injury. Active filings in this dataset span 2017–2023 across US, WO, CA, IN, CN, and AU jurisdictions, with Takeda Pharmaceutical Company Limited appearing on the AU-jurisdiction filing — reflecting the corporate succession from NPS to Shire-NPS to Takeda.

GLP-1/GLP-2 Dual Agonism (Zealand Pharma)

Zealand Pharma A/S holds the sole retrieved patent covering GLP-1/GLP-2 dual agonism — an active European patent published in 2026 covering a composition comprising a GLP-1/GLP-2 dual agonist for treatment or prevention of diarrhea, loose stools, urgency, incontinence, and high fecal/stomal output in post-bowel-resection patients. This modality targets both incretin and intestinotrophic pathways simultaneously, potentially addressing gut motility (via GLP-1) and mucosal trophism (via GLP-2) in a single molecular entity — the most structurally differentiated entry in the dataset.

The IP landscape is dominated by Shire-NPS/Takeda continuation families rooted in a 2004 priority date (U.S. Provisional Application No. 60/623,233, filed November 1, 2004). While many individual US continuations are inactive, a subset remain active across multiple jurisdictions (US, WO, CA), creating a complex freedom-to-operate environment for next-generation GLP-2 analog developers seeking to differentiate via formulation, schedule, or indication. Zealand Pharma’s active EP filing, with a 2026 publication date, represents a recent and commercially significant IP position deserving close monitoring by competitors, as noted in analyses available via resources such as the European Patent Office.

Clinical and real-world evidence: what the data show

The clinical evidence base for GLP-2R agonism in SBS spans a pivotal RCT, multiple real-world cohorts, a post-marketing registry, and a pediatric systematic review — collectively establishing a robust efficacy signal for teduglutide while revealing meaningful gaps in uptake and access.

The pivotal Rigshospitalet RCT (2011, n=83) established the efficacy benchmark: subcutaneous teduglutide 0.05 mg/kg/day produced ≥20% reductions in parenteral support volumes at weeks 20 and 24 versus placebo. Dose-response data were also reported for 0.10 mg/kg/day. The University of Tübingen retrospective cohort (2018, n=14) extended this signal into real-world practice, reporting 11.0% parenteral support reduction at 24 weeks and 36.6% at 48 weeks, with GLP-2R expression quantified in mucosal tissue as a potential biomarker for clinical response.

The largest real-world dataset in the retrieved literature comes from the Inserm/Paris post-marketing cohort (2023): 331 SBS-CIF patients followed in an expert home parenteral support center between 2015 and 2020, with teduglutide initiated in only 56 patients (16.9%). This low uptake rate documents treatment barriers including cost — a signal with direct implications for the commercial positioning of next-generation agents. The Medical University of Vienna contributed a notable case report (2021) describing teduglutide used as “bridging therapy” to intestinal reconstruction, with the patient achieving enteral autonomy prior to surgery — a novel use case distinct from chronic maintenance therapy and consistent with the perioperative indication claimed in Shire-NPS peptibody patents.

A Harvard Medical School case series (2020, n=18 patients, 19 kidney transplants) documented teduglutide use in SBS complicated by kidney transplantation, with dramatic diarrhea reduction — illustrating the drug’s utility in complex specialty comorbidity settings. The Meyer Children’s Hospital systematic review (Florence, 2022) confirmed pediatric approval for GLP-2 analog therapy in 2016, providing a framework for evaluating next-generation agents in this underserved population. All of this real-world evidence is consistent with registry data tracked by bodies such as the National Institutes of Health and reviewed in guidelines published by the World Health Organization.

No clinical data specific to glepaglutide, apraglutide, GLP-2 peptibodies (K274/B264), or the Zealand Pharma GLP-1/GLP-2 dual agonist were present in the retrieved results beyond their identification as pipeline agents — underscoring the importance of ongoing patent and literature monitoring for these programs.

Preclinical regeneration signals: Wnt, EGF, and transcriptome-guided approaches

Beyond GLP-2R agonism, the retrieved dataset contains several preclinical signals for non-GLP-2 regenerative strategies that may inform future combination regimens or independent drug programs — though all remain exclusively preclinical in this dataset.

Wnt Signaling and BSDL

Investigators at Xinhua Hospital (Shanghai Jiao Tong University) showed that bile salt dependent lipase (BSDL) administration in SBS rats improved intestinal adaptive growth and barrier function, with the mechanism mediated at least partly via Wnt signaling molecules. This finding positions Wnt pathway activation as a downstream mediator of intestinal adaptive growth in response to BSDL — providing a non-GLP-2 regenerative target for future investigation.

GLP-2 and EGF Cooperativity

A pediatric case report from Children’s Hospital Regina Margherita (Turin, 2022) highlighted GLP-2 receptor signaling operating in concert with epidermal growth factor (EGF) to enhance mucosal restoration. The mechanistic co-operation between GLP-2R and EGF receptor (EGFR) pathways suggests potential for combination regimens targeting both receptors to amplify intestinal regeneration beyond what either agent achieves alone.

NOD2 as a Precision Medicine Modifier

Murine SBS studies from Rostock University Medical Center (2020) identified NOD2 (nucleotide oligomerization domain 2) genotype as a modifier of teduglutide response, specifically in the context of intestinal barrier tight junction pore function. NOD2 dysfunction was shown to predispose to intestinal failure post-resection, while teduglutide’s barrier-repair effects were modulated by NOD2 status — with implications for patient selection in precision medicine approaches to SBS therapy.

Transcriptome-Guided Regeneration

RNA-seq profiling of a surgical neointestinal regeneration model at Chang Gung Memorial Hospital (Taiwan, 2018) identified distinct gene ontology signatures distinguishing intestinal adaptation from neoregeneration at early time points. Cell cycle and DNA replication processes were enriched in week-1 adaptation conditions, while immune-related gene ontology pathways characterised week-1 neoregeneration — providing a data-driven framework for identifying growth factor co-targets beyond GLP-2 to include in regenerative combination regimens.

GLP-2 and Microbiome Stabilisation

A preclinical paper from Nanjing University of Chinese Medicine (2021) investigated GLP-2 therapy’s effect on intestinal bacterial and fungal dysbiosis in type 2 SBS rats (80% small bowel resection + ileocecum resection + jejunocolostomy model), using 16S rRNA and ITS sequencing. The findings establish GLP-2’s potential immunomodulatory and microbiome-stabilising properties as secondary therapeutic mechanisms, suggesting that microbiome restoration may constitute an additional benefit of GLP-2R agonists — and potentially supporting future combination with microbiome-targeted therapies.

Strategic implications for drug developers, IP strategists, and investors

The SBS drug pipeline presents a set of clearly delineated strategic opportunities and IP risks that are directly readable from the patent and literature signals in this dataset.

Freedom-to-operate complexity: The IP landscape is dominated by Shire-NPS/Takeda continuation families rooted in a 2004 priority date. While many individual US continuations are inactive, a subset remain active across multiple jurisdictions (US, WO, CA), creating a complex freedom-to-operate environment for next-generation GLP-2 analog developers seeking to differentiate via formulation, schedule, or indication. Any developer of a next-generation GLP-2 analog must conduct careful FTO analysis against this continuation estate, particularly for perioperative and CiC-specific indications.

Patient stratification as IP strategy: Patient stratification by anatomy (colon-in-continuity vs. end-jejunostomy) and by GLP-2R expression level appears to be a translatable precision medicine opportunity, supported by both real-world receptor expression data from the University of Tübingen and a dedicated patent family from NPS Pharmaceuticals. Developers of next-generation agents should consider including GLP-2R expression as a companion biomarker endpoint to differentiate from the existing Shire-NPS/Takeda estate and to build proprietary patient selection IP.

Pediatric SBS as a validated commercial opportunity: Retrieved results confirm pediatric approval for teduglutide (2016) and a systematic review documenting PN-reduction efficacy in children. Next-generation analogs with improved tolerability or dosing convenience — such as the extended half-life enabled by Fc-fusion peptibody formats — could capture significant unmet clinical need in this indication, which remains underserved relative to the adult SBS population.

Zealand Pharma’s dual agonist as a monitoring priority: The GLP-1/GLP-2 dual agonist patent (Zealand Pharma, EP, active, published 2026) is structurally the most differentiated entry in the dataset. Its active legal status and recent publication date suggest it is a commercially significant IP position. Competitors developing GLP-2 analogs for post-resection GI symptom management should monitor this filing and its prosecution history closely. Patent databases maintained by bodies including the European Patent Office provide the most direct access to prosecution status updates.

“The GLP-1/GLP-2 dual agonist patent from Zealand Pharma — active, published 2026 — is the most structurally differentiated entry in the SBS patent dataset, targeting both incretin and intestinotrophic pathways in a single molecular entity.”

Combination and emerging directions: The convergence of GLP-2 + EGF cooperativity, GLP-2 + microbiome effects, and transcriptome-guided growth factor identification points toward a future combination therapy paradigm in SBS. Developers with platform capabilities in growth factor biology, microbiome modulation, or Wnt pathway targeting may find meaningful partnership or co-development opportunities with GLP-2R agonist programs — particularly as the field moves toward next-generation analogs and perioperative indications. Innovation intelligence platforms such as PatSnap’s life sciences tools provide the cross-patent and cross-literature analysis needed to map these convergence points systematically.